Brian Hilberdink
In his current role as President of Novo Nordisk Canada, he has significantly increased investment in Canada, launched several innovative products in the therapy areas of diabetes, obesity and hemophilia, and the company has been recognized as one of the country’s top 100 employers.
Brian is an active contributor on the Board of Innovative Medicines Canada and Biotech Canada and is also a founding member of the Diabetes Canada Impact Council and the City of Mississauga’s Life Science Consortium.
Previous to his current role, Brian was a Corporate Vice President in Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark, leading the launch of the company’s future insulin portfolio; at the time, this represented the single largest investment ever made in the history of diabetes drug development. He also has experience working in the United States, where he led several commercial teams during a period of significant growth and investment.
Articles: Brian Hilberdink
“Canada Needs to do Better in Supporting Innovative Biopharma”
Opinion / Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada. I’ve often wondered how things would be if Canada had steadily continued a path of biopharmaceutical discovery and commercialization after Banting and Best’s breakthrough in 1921, and what our economy, our healthcare system…
Putting Canadian Patients’ Health First
Canada / Brian Hilberdink, President of Novo Nordisk Canada, calls for collaboration between government and industry to ensure that Canadian patients get swift access to the best treatments. As a Canadian who spent several years working globally for a biopharmaceutical company, I saw firsthand how pricing and investment decisions can be made to better support healthcare innovation…
Latest Report
